BioSpace News Archive

Clover Biopharmaceuticals, Ltd. and the International Vaccine Institute announced that Clinical Infectious Diseases has published additional data from SPECTRA, a global Phase 2/3 clinical trial, that showed vaccination with SCB-2019 reduced the risk of transmitting SARS-CoV-2 infection to household members, compared to placebo participants.

The University of Aizu collaborated on development of the technology designed to help verify individuals’ identity and protect data integrity.

Optinose today provided corporate updates and announced that CEO Peter Miller will participate in a fireside chat at the 34th Annual Piper Sandler Healthcare Conference on December 1, 2022.

HOOKIPA Pharma Inc. today announced that the company will participate virtually in investor meetings and panel discussions at The JMP Securities Hematology and Oncology Summit, December 6 - 7, 2022.

Tonix Pharmaceuticals Holding Corp. today announced data from its fully human anti-SARS-CoV-2 monoclonal antibody platform in an oral presentation delivered by Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, at the World Antiviral Congress 2022 in San Diego, Calif.

Aridis Pharmaceuticals, Inc. today announced the closing of patient enrollment in the multiple ascending dose (MAD) and dose-ranging cohorts in the Phase 2a clinical trial of AR-501 in cystic fibrosis (CF) patients.

The results of a clinical trial using software from XRHealth, developer and operator of virtual treatment rooms in the metaverse, published in MDPI highlights that the combination of virtual reality and artificial intelligence reduces hot flashes and improves the overall psychological well-being of women with breast and ovarian cancer.

Chemomab Therapeutics, Ltd. today announced the appointment of Mitchell L. Jones , MD, PhD, as Vice President of Corporate Development & Strategy.

Terray Therapeutics today announced the appointment of Bassil Dahiyat, Ph.D., as an Independent Director.

Pathios Therapeutics Limited (“Pathios”), a biotech company focused on developing first-in-class therapies for cancer, today announced that Jeanmarie Guenot , Ph.D., has been appointed as a non-executive director to the company’s board of directors.